CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,000 enrolled
Drug / intervention
Sentinel® Cerebral Protection Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04149535
NCT04149535N/ACompleted
CompareCT.gov

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter

Boston Scientific Corporation·interventional·Posted Nov 4, 2019·Updated Feb 2, 2023

In Brief

A clinical study evaluating Sentinel® Cerebral Protection System for Stroke. Completed, enrolled 3,000 participants across 57 sites in 6 countries.

Detailed Summary

To demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the risk of peri-procedural stroke (≤72 hours) after transcatheter aortic valve replacement (TAVR).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesAustralia, Denmark, France, Germany, Italy, United States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 4, 2019
Enrollment StartFeb 7, 2020
Primary CompletionFeb 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.7 years ago

Interventions

Sentinel® Cerebral Protection Systemdevice

cerebral embolic protection system